(Colorectal Cancer) Is Panitumumab Plus FOLFOXIRI Effective?
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
Panitumumab Plus FOLFOXIRI in RAS Wild-Type Metastatic Colorectal Cancer
- December 30, 2019
- Reading time: 2 minutes
Updated: February 13, 2020
On October 10, 2019, Dominik P. Modest published in the Journal of Clinical Oncology the VOLFI/AIO KRK0109 Phase 2 trial results: "Efficacy and safety of anti-EGFR antibody panitumumab (Vectibix) plus FOLFOXIRI chemotherapy in treatment-naive RAS wild-type metastatic colorectal cancer patients."
Trial Design
The VOLFI/AIO KRK0109 Phase 2 trial was an open-label study in 96 treatment-naive patients with RAS wild-type metastatic colorectal cancer, randomized 2:1 to:
- Panitumumab + FOLFOXIRI group (N=63)
- FOLFOXIRI group (N=33)
Primary endpoint: ORR. Secondary endpoints: secondary resection rate, OS, and PFS.
Efficacy Results
ORR (primary endpoint):
- Panitumumab + FOLFOXIRI group: 87.3% / FOLFOXIRI group: 60.6%
- The panitumumab + FOLFOXIRI group exceeded the trial's predefined threshold (75%) and was significantly higher than FOLFOXIRI alone
Secondary resection rate:
- Panitumumab + FOLFOXIRI group: 33.3% / FOLFOXIRI group: 12.1% — improved in the combination group
Both groups had similar PFS. OS was also improved in the panitumumab + FOLFOXIRI group.
Conclusions
Based on the VOLFI/AIO KRK0109 trial results, Dominik P. Modest concluded that anti-EGFR antibody panitumumab plus FOLFOXIRI improved both objective response rate and resection rate compared to FOLFOXIRI alone in treatment-naive RAS wild-type metastatic colorectal cancer patients, making it a promising new treatment option for this population.
Source: FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). J Clin Oncol. 2019 Oct 14.
Tags: #ColorectalCancer #Panitumumab #Vectibix
- Clinical trial drug
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4